Stereotactic ablative radiotherapy (SABR) is a relatively novel form of high precision radiotherapy. For low- and intermediate risk patients, ultrahypofractionation (UHF - more than 5 Gy per day) has been compared to conventionally fractionated or moderately hypofractionated radiotherapy in two large randomized studies. A third smaller randomized study examined the question of the optimal frequency of treatments. The results of these studies will be reviewed. SABR for high risk prostate cancer has been shown to be feasible and is well tolerated with careful planning and setup techniques. However, there is currently insufficient data supporting its use for high-risk patients to offer SABR outside of a clinical trial. SABR costs less to the radiotherapydepartments and, the patient, as well as increasing system capacity. Therefore, it has the potential to be widely adopted in the next few years.

中文翻译：

---

立体定向烧蚀身体放疗用于中度或高危前列腺癌。

立体定向消融放疗（SABR）是高精度放疗的一种相对新颖的形式。对于中低风险患者，在两项大型随机研究中，已将超低分割（UHF-每天超过5 Gy）与常规分割或中等分割的放射治疗进行了比较。第三项较小的随机研究检查了最佳治疗频率的问题。这些研究的结果将进行审查。SABR用于高危前列腺癌已被证明是可行的，并且经过精心的计划和设置技术可以很好地耐受。但是，目前尚无足够的数据支持其用于高危患者在临床试验之外提供SABR。SABR对放射治疗部门和患者的成本更低，并且增加了系统容量。因此，